H uman hepatocellular carcinoma (HCC) is emerging as the sixth most common carcinoma and the third leading cause of cancer-associated mortality worldwide. Aggressiveness, invasiveness (in particular, intrahepatic), and frequent postoperative recurrence are the most significant characteristics of HCC.
H uman hepatocellular carcinoma (HCC) is emerging as the sixth most common carcinoma and the third leading cause of cancer-associated mortality worldwide. Aggressiveness, invasiveness (in particular, intrahepatic), and frequent postoperative recurrence are the most significant characteristics of HCC. (1, 2) In this regard, elucidation of the mechanisms underlying HCC initiation and early metastasis is essential to improve both early diagnosis and prognosis.
Cluster of differentiation 97 (CD97) is a member of the epidermal growth factor (EGF) seven-transmembrane subfamily belonging to the class B G protein-coupled receptor (GPCR) group. (3) (4) (5) CD97 was originally identified in hematopoietic cells and abundantly detected in numerous carcinoma types in subsequent studies. The roles of CD97 cascades in gastric, colorectal, thyroid, esophageal, pancreatic, cerebral, and oral squamous cell carcinoma initiation and progression have become an increasing focus of research in 1866 recent years. (6) (7) (8) (9) (10) (11) (12) Based on its expression patterns and extracellular EGF-like domain region, CD97 is proposed to be involved in cellular adhesion through interactions with other cell surface and extracellular matrix proteins. (13) The ligand CD55 binds CD97 through its EGF-like repeat structure, with the highest affinity to EGF (1, 2, 5) relative to other isoforms, which governs cancer invasion and metastasis. (14) (15) (16) Accumulating evidence indicates that both CD97 and CD55 are involved in tumor dedifferentiation, migration, invasiveness, and metastasis. (17) Recent study reveals the significant prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. (18) In view of its established roles in tumor invasion and signaling, CD97 presents an exciting novel therapeutic target. However, the specific biological role of CD97 in HCC remains to be established.
Abbreviations: 5-Aza-dC, 5-aza-2′-deoxycytidine; CD97, cluster of differentiation 97; co-IP, coimmunoprecipitation; E-cad, E-cadherin; EGF, epidermal growth factor; EMT, epithelial-mesenchymal transition; GPCR, G protein-coupled receptor; GRK6, GPCR
Receptor internalization, which relies on the recruitment of arrestins, is a common mechanism for GPCR desensitization and down-regulation. The immunofluorescence technique is widely used to visualize and verify this internalization process. (19) Once activated by ligand, GPCRs initiate a highly conserved signaling byinteractions with GPCR kinases (GRKs), which phosphorylate activated conformations of receptors and β-arrestins, which next bind to the phosphorylated receptors to mediate desensitization of G protein signaling and receptor internalization. (20, 21) Notably, β-arrestins are important trafficking elements, which eventually lead to GPCR internalization and degradation. Structurally, β-arrestin1 was reported to bind a GPCR phosphopeptide. (22) Recently, the crystal structure of the rhodopsin-arrestin complex was solved using an X-ray or X-ray-free electron laser. (23) However quantities of GPCRs lack solved structures involving CD97. Homology models are extensively used to predict GPCR structures by comparing to templates with solved structures that are similar to the unknown structure of interest. For instance, Leffler et al. (24) used nicotinic acetylcholine receptor homology models to identify peptide ligands. Here, we have employed previously reported glucagon-like peptide-1 receptor (GLP1R) as a template for CD97 transmembrane domain homologous modeling. (25) GRKs phosphorylate specific residues in the cytoplasmic domains of activated GPCRs, which is a critical step for the recruitment and binding of arrestins. GRKs modulate the responses to many GPCRs involved in tumor signaling and act as hubs regulating several cellular processes related to cancer progression through interactions with other components of the signal-transduction cascades. (26, 27) Recent studies have shown that GRK6 deficiency promotes tumor metastasis through consequent up-regulation of metastasis-mediating matrix metalloproteinases (MMPs). (28) In the current study, we demonstrate that CD97 promotes HCC metastasis. Homology modeling and co-immunoprecipitation (co-IP) assays were used to predict and confirm the CD97/β-arrestin1 interface. Integrated regulatory interactions were further detected between GRK6 and CD97, leading to enhanced downstream MMP secretion in human HCC.
Materials and Methods

patieNt SaMpleS
Data were obtained from 140 paired HCC fresh tissues (including tumors and adjacent normal samples) and 15 normal liver tissues (hepatic hemangioma patients) acquired between August 2012 and September 2013 at The First Affiliated Hospital of Nanjing Medical University (Nanjing, China). The age of HCC patients ranged from 26 to 86 years, and aRtiCle iNFoRMatioN: 1867 the mean age was 53.25. Informed consent for tissue analysis was obtained before surgery. The study was approved by the Institutional Ethics Committee of Nanjing Medical University. Detailed characteristics of HCC patients and controls are listed in Table 1 . All research was performed in compliance with government policies and the Helsinki declaration. All experiments were undertaken with the understanding and written consent of each subject.
Detailed information regarding cell culture, quantitative real-time PCR, ectopic expression and gene silencing, western blot, co-IP assay, immunohistochemical (IHC) assay, wound healing assay, cell migration and invasion assay, metastasis model, human protease antibody array, enzyme-linked immunosorbent assay, mass spectrometry, homology modeling, and statistical analysis is provided in the Supporting Information.
Results
CD97 poSitiVity iN HCC iS CoRRelateD WitH pooR pRogNoSiS
We initially detected CD97 expression in 140 pairs of HCC and corresponding adjacent tissue samples and 15 normal liver samples using an IHC assay, western blot, and quantitative real-time PCR analyses (Fig. 1A-C) . Differences in expression of CD97 were detected in human HCC and in paired adjacent and normal samples ( Fig. 1A-C; Supporting Fig. S1A ). Based on the integrated optical density (IOD) value of IHC staining, we divided the HCC patients into two groups: CD97-high (n = 32) and CD97-low (n = 108), according to the upper 95% confidence interval of CD97 expression in adjacent samples. The tumor margins and centers were further compared in the IHC stained sections, which presented more staining at the margin area (Supporting Fig. S1B ). Given that CD55 was proved to be the ligand of CD97, we also confirmed the CD55 expression pattern in human HCC and in paired adjacent and normal samples, where a positive correlation with CD97 was detected (Supporting Fig. S1C-E) .
Kaplan-Meier analysis was performed to determine whether CD97 expression was associated with overall and relapse-free survival of HCC patients. Our findings revealed a statistically significant association of CD97 with overall survival (P = 0.015) (Fig. 1D) . Furthermore, patients with high CD97 expression presented poorer relapse-free survival relative to the CD97-low group to a statistically significant extent (P = 0.006) (Fig. 1E) . Based on the IOD value of IHC staining, HCC patients were divided into two groups: CD97-high (n = 32) and CD97-low (n = 108), according to the upper 95% confidence interval of CD97 expression in adjacent samples. *P < 0.05. Abbreviations: AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
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According to clinical characteristics, CD97 expression was significantly correlated with increased vascular invasion (P = 0.002), intrahepatic metastasis (P < 0.001), distant metastasis (P < 0.001) ability, and tumor size (P = 0.025). In contrast, no positive correlation was found in relation to age, gender, hepatitis B surface antigen, hepatitis C virus, cirrhosis, alpha-fetoprotein, and Edmondson grade (Table 1) . Correlation analysis of CD97 with clinicopathological characteristics showed that CD97 was highly correlated with HCC metastasis. Patients were divided into CD97-high (n = 32) and CD97-low (n = 108) groups. Each experiment was performed in triplicate. P < 0.05 was regarded as statistically significant. ***P < 0.001, **P < 0.01, and *P < 0.05. Abbreviations: N, normal; n.s., nonsignificant; P, paratumor; T, tumor.
CD97 pRoMoteS Cell MetaStaSiS IN VITRO
The biological function of CD97 was further investigated in vitro. Quantitative real-time PCR and western blot analyses were used to detect mRNA and protein levels of CD97 in HCC cell lines, respectively ( Fig. 2A) . Based on these findings, SMMC-7721 cells with stable down-regulation of CD97 and Huh7 cells with stable ectopic overexpression of CD97 were generated, and transduction efficiencies were measured ( Fig. 2D,E; Supporting Fig. S6A ).
Based on the canonical pattern, GPCR activation after ligand stimulation is the prerequisite for GPCR functioning. And internalization, which leads to endocytosis and degradation of GPCR, is one of the predominant mechanisms controlling GPCR signaling to ensure the appropriate cellular responses to stimuli. To visualize the internalization of CD97, the high CD97 expressing SMMC-7721 cells with or without CD55 treatment were detected at three time points (0, 30, and 60 minutes) using an immunofluorescence technique. The results showed that CD97 continuously located on cytomembrane without CD55 stimulation. On the contrary, the subcellular location of CD97 transferred from the cytomembrane to the cytoplasm over time, which confirmed the existence of CD97 internalization (Fig. 2C ).
Correlation analysis of CD97 with clinicopathological characteristics showed that CD97 promotes HCC metastasis. Because accumulating evidence confirms the stimulating effect of CD55 during the function of CD97 in tumor biological properties, wound healing and transwell assays were conducted with or without stimulation of CD55 to establish the specific role of CD97 in HCC cell invasion and migration. When treated with CD55, the migration and invasion abilities of Huh7 cells significantly increased under conditions of CD97 overexpression and, conversely, decreased upon CD97 knockdown in SMMC-7721 cells (Fig. 2F,G) . However, no significant difference was observed in the absence of CD55 (Supporting Fig. S2B,D) . Our results clearly supported a promoting effect of CD97 on migration and invasion in HCC cells.
HoMology MoDeliNg oF CD97 aND eStaBliSHMeNt oF a tHRee-DiMeNSioNal MoDel oF tHe CD97/β-aRReStiN1 CoMpleX
CD97 belongs to the GPCR adhesion receptor family. The three-dimensional structure of the transmembrane domain for this family is yet to be determined.
The closest structural homolog of CD97 is the gastrin receptor (both belong to the class B GPCR family). We selected GLP1R as a template for CD97 transmembrane domain homologous modeling.
β-Arrestin is able to interact with most GPCRs. The protein regulates cell signaling pathways by blocking the interactions of GPCR with G protein. GPCR and β-arrestin interactions have been verified based on the structure of the human rhodopsin/mouse S-arrestin (protein databank, 4ZWJ) fusion protein complex. We predicted the key domains of CD97/β-arrestin1 interactions using homology modeling (Fig. 3A, shown in blue). The data showed that β-arrestin1 binds the CD97 intracellular domain and key domains located within the intracellular loop (ICL) 1 (480-486), transmembrane helix (TMH) 3-ICL2 (550-552), ICL3-TMH6 (631-641), and TMH7-8 (697-699). To confirm the CD97/β-arrestin1 interactions, the co-IP assay was performed. The CD97/β-arrestin1 complex was pulled down using either CD97 or β-arrestin1 antibody and further immunoblotted with anti-β-arrestin1 or CD97. We confirmed equal loading amounts of CD97 and β-arrestin1. Bidirectional co-IP verified the presence of the CD97/β-arrestin1 complex (Fig. 3B) . Pull-down proteins obtained using the CD97 antibody were subsequently processed and subjected to mass spectrometric analysis, followed by evaluation with the Proteome Discoverer Program and the National Center for Biotechnology Information protein database with the Mascot search engine. Mass spectrometric data revealed that the pull-down proteins contained a peptide fragment that most closely matched human β-arrestin1 (Fig. 3C) .
According to the homology model, we predicted the potential CD97/β-arrestin1 binding sites and generated four mutations in CD97 for further analysis (Fig. 3D) . Based on the prediction, we validated the CD97/β-arrestin1 binding sites through co-IP analysis of the CD97 mutants. CD97 mutation 3 presented the weakest binding to β-arrestin1 relative to CD97 wild-type and the other three mutations, indicating that ICL3-TMH6 (631-641) is the most likely potential CD97/β-arrestin1 binding site ( Fig. 3E; Supporting Fig. S4B-H) .
iNtegRateD RegulatoRy iNteRaCtioNS BetWeeN CD97 aND gRK6 pRoMote MMp2 aND MMp9 SeCRetioN iN HCC
The mechanisms underlying the significant HCC metastasis-promoting activity of CD97 in vitro and in vivo were further investigated. To this end, shRNA and CD97 Lv, respectively, under CD55 stimulation (original magnification ×100). (G) The in vitro migration and invasion abilities of SMMC-7721 and Huh7 cells lentivirally transduced with CD97 shRNA or CD97 Lv were assessed using a Transwell assay under CD55 stimulation (original magnification ×200). Each experiment was performed in triplicate, and data from the experimental and control groups were compared. P < 0.05 was regarded as statistically significant. *P < 0.05 and **P < 0.01. 1871 a metastasis-associated protease array was used to uncover the critical downstream molecules and signaling pathways. Total protein of SMMC-7721 cells transfected with specific CD97 short hairpin RNAs (shRNAs) and shRNA normal control (NC) was extracted as samples for loading. Notably, MMP2 and MMP9 expression patterns presented the most significant differences between the groups (Fig. 4A) . Western blot was subsequently conducted to detect MMP2/9 expression in SMMC-7721 cells transfected with CD97 shRNA/CD97 shRNA-NC and Huh7 cells transfected with CD97 lentivirus (Lv)/ CD97 Lv-NC with or without CD55 ligand stimulation. CD97 expression was positively correlated with that of MMP2/9 under conditions of CD55 stimulation in both SMMC-7721 and Huh7 cells but not in the absence of CD55 (Fig. 4B) . Similar results were obtained with enzyme-linked immunosorbent assay (ELISA) conducted to determine MMP2/9 secretion in the supernatant fractions of SMMC-7721 and Huh7 cells (Fig. 4C) . Our findings indicate that activation of CD97 under conditions of CD55 stimulation is essential to facilitate downstream alterations and that overexpression of CD97 triggers up-regulation of MMP2 and MMP9.
GRK family members are critical molecules in GPCR phosphorylation after receptor activation. This step promotes intracellular β-arrestin recruitment and binding to activated GPCRs, resulting in receptor inactivation and internalization and ultimate suppression of GPCR expression. GRK6 has been identified as a regulator of MMPs, such as MMP2/9. (24) Meanwhile, β-arrestin1 is essential during the process of GPCR internalization and devitalization following signaling. In view of the above evidence, we examined whether GRKs and β-arrestin1 are critical in the process of HCC metastasis mediated by CD97. Given that GRK2 and GRK6 are expressed in liver cancer and that CD97 and β-arrestin1 interact to form a complex, we explored the potential correlations of 1872 GRK2, GRK6, and β-arrestin1 with CD97 in HCC using IHC, western blot, and Pearson correlation analyses. IHC experiments revealed that GRK6, but not GRK2, was negatively associated with CD97 expression in HCC tissues, while no correlation was evident between CD97 and β-arrestin1 (Fig. 4D) . Consistent data were obtained with Pearson correlation analysis based on quantitative real-time PCR data (Supporting Fig. S5A) . Accumulating evidence has shown that down-regulation of GRKs promotes GPCR cascades. Accordingly, we explored the impact of the correlation between CD97 and GRK6 on downstream signaling. Huh7 cell lines were transfected with CD97 overexpression (CD97 + ), GRK6 overexpression (GRK6 + ), and GRK6 shRNA (GRK6 -) Lvs, followed by validation with quantitative real-time PCR (Supporting Figs. S5B and S6C). All groups were treated with CD55 to ensure activation of CD97. Western blot data revealed that overexpression of GRK6 led to suppression of CD97. The integrated regulatory interactions between CD97 and GRK6 induced alterations in MMP2 and MMP9 expression (Fig. 4E) . To further investigate the regulatory interactions between CD97 and β-arrestin1, Huh7 cells were transduced with CD97 overexpression (CD97 + ), β-arrestin1 overexpression (β-arrestin1 + ), and β-arrestin1 shRNA (β-arrestin1 -) Lvs. The transduction efficiencies are shown in Supporting Figs. S5C and S6B. Notably, overexpression of β-arrestin1 had no effect on CD97, while its knockdown enhanced CD97 levels. MMP2 and MMP9 levels were positively regulated by CD97, regardless of β-arrestin1 (Fig. 4F) . Our findings indicate that β-arrestin1 is essential for the process of CD97 internalization and down-regulation but that overexpression of β-arrestin1 could not promote internalization and down-regulation of CD97. Based on the collective results, we conclude that CD97 ). Metastasis was monitored using the IVIS Lumina II image system, and tumors with volumes >2 mm 3 were compared in each group. The results showed significant enhancement of metastatic ability in the CD97 overexpression group relative to the paired control group. Knockdown of GRK6 (CD97 + GRK6 -) heightened the CD97-mediated metastasis-promoting effect compared with the CD97 overexpression (CD97 Lv) group. Conversely, GRK6 overexpression (CD97   +   GRK6 + ) attenuated the metastasis-enhancing role of CD97 (Fig. 5A,B) . The metastatic tumors in each group were further analyzed by hematoxylin and eosin staining, with similar results (Fig. 5C ). Taken together, these findings suggest that CD97 promotes metastasis of HCC through integrated regulatory interactions with GRK6 in vivo.
CD97 eNHaNCeS tuMoR
HigH MetHylatioN Rate iNDuCeS tHe DoWNRegulatioN oF gRK6 iN CD97-HigH HCC
MMPs are reported to facilitate metastasis by inducing epithelial-mesenchymal transition (EMT). Here, we selected an epithelial marker, E-cadherin (E-cad), and a mesenchymal marker, vimentin (VIM), as metastasis biomarkers of MMP-induced EMT. Integrated regulatory interactions between CD97 and GRK6 in HCC metastasis were further analyzed in mouse metastases located in the lung by detection of E-cad/ VIM expression and location using IHC (Fig. 6A) . CD97 overexpression accelerated EMT potential, which was associated with low E-cad and high VIM expression compared with the control. GRK6 knockdown markedly enhanced the EMT potential of CD97 + Huh7 cells (CD97   +   GRK6 -group), as reflected by higher expression of VIM and increased down-regulation of E-cad compared with the CD97 overexpression (CD97 Lv) group. Conversely, GRK6 overexpression (CD97 +   GRK6 + ) impaired EMT potential relative to CD97 overexpression (CD97 Lv group).
To further elucidate the mechanism underlying the suppression of GRK6 in CD97-high HCCs, we investigated methylation in the promoter region of GRK6 based on CpG island prediction using MethPrimer (http://www.urogene.org/methprimer/) and University of California Santa Cruz genome bioinformatics (http://genome.ucsc.edu) (Fig. 6B) . The methylation primer is presented in Supporting Table S1 . CD97-high HCC tumor tissues (n = 32) and CD97-low tumor tissues (n = 108) were included in the bisulfite PCR. The methylation rate of the GRK6 promoter was significantly higher in CD97-high tumor tissues of HCC patients than in CD97-low tumor tissues (Fig. 6C) . Methylation-specific PCR of GRK6 validated this finding (Fig. 6D) . Meanwhile, we detected GRK6 expression by quantitative real-time PCR, which revealed negative correlation with its DNA methylation rate (Fig. 6E) . To further validate the negative correlation in HCC, SMMC-7721 and Huh7 cells were treated with varying concentrations of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5-Aza-dC). Treatment of HCC cells with 5-Aza-dC led to a dose-dependent restoration of GRK6 expression, suggesting a negative correlation between DNA methylation and GRK6 expression (Fig. 6F,G) . Taken together, these data indicated that the down-regulation of GRK6 in HCC was attributed to hypermethylation of the promoter region of GRK6.
Discussion
GPCRs represent a diverse and biologically ubiquitous group of protein receptors. The EGF seven-span transmembrane family consists of adhesion GPCRs with a diverse functional repertoire. CD97 is the most broadly expressed member with several roles in cell adhesion, migration, and regulation of 1874 intercellular junctions. (29) The protein is additionally expressed in a variety of human malignancies, including those of the thyroid, stomach, colon, and brain as well as intrahepatic cholangiocarcinoma. (4) (5) (6) (7) (8) (9) (10) (11) (12) 18) CD97 confers an invasive phenotype and is correlated with tumor grade, lymph node invasion, metastatic spread, and overall prognosis. (5, 8, 11, 30) In the present study, we investigated the potential biological function of CD97 in development of HCC. Though correlation was detected between CD97 expression and tumor size (P = 0.025) according to clinical characteristics, no statistically significant differences were found in the further cell proliferation-related experiments (Supporting Fig. S3A,B) . Our results clearly demonstrate that CD97 is up-regulated in the subset of HCC patients with metastatic potential, suggesting that it plays a role in promoting HCC metastasis.
While GPCR signaling is essential, its overstimulation can be deleterious, resulting in cellular toxicity or uncontrolled cellular growth. Accordingly, nature has developed a number of physiological mechanisms to limit GPCR signaling, which are broadly referred to as "desensitization" and involve a decrease in response to repeated or continuous stimulation. (31) Once activated by agonists, receptor internalization mediated by phosphorylation-dependent recruitment of arrestins is a critical step for GPCR desensitization and down-regulation. Our findings verify the vital stimulation role of the ligand CD55 in CD97 activation, functionality, and desensitization. Without CD55 stimulation, CD97 failed to be activated and play the promoting role during HCC metastasis. A recent study using single-molecule fluorescence microscopy to visualize in real time the internalization of GPCR supports our conclusions with respect to the function of ligand stimulation. (32) Changes in GPCR expression or functionality may trigger tumor progression through β-arrestin-dependent receptor cascades. (33) (34) (35) GPCR and β-arrestin interactions have been verified based on the structure of the human rhodopsin/ mouse S-arrestin (protein databank, 4ZWJ) fusion protein complex. (25) Zhou et al. (23) reported an X-rayfree electron laser crystal structure of the rhodopsinarrestin complex. CD97/β-arrestin1 binding sites were . Experiments were performed in triplicate independently; P < 0.05 was regarded as statistically significant. *P < 0.05, **P < 0.01. Abbreviation: HE, hematoxylin and eosin.
predicted and confirmed by our group with the aid of homology modeling, providing preliminary evidence of interactions between these two proteins, which is the structural foundation for β-arrestin1-participating CD97 internalization and degradation. Knockdown of β-arrestin1 resulted in up-regulation of CD97, while The bisulfite sequencing method was applied to detect the methylation rate predicted in GRK6. Black dots indicate the methylation points. Methylation of GRK6 DNA was analyzed, and the CD97-high group presented a higher GRK6 methylation rate compared with the CD97-low group. (D) DNA methylation status of GRK6 was assessed by a methylation-specific PCR assay in CD97-high and CD97-low HCC samples. (E) Relative mRNA expression of GRK6 was examined. (F,G) GRK6 methylation rate and relative mRNA levels were evaluated in SMMC-7721 and Huh7 cell lines treated with 5-aza-dC and dimethyl sulfoxide as control. Each experiment was performed in triplicate independently; P < 0.05 was regarded as statistically significant. **P < 0.01. DAC, 5-aza-dC; DMSO, dimethyl sulfoxide; M, methylated; MSP, methylationspecific PCR; U, unmethylated.
overexpressing β-arrestin1 could not affect CD97 expression, which indicates the necessary but not sufficient role of β-arrestin1. β-Arrestin1 just acts as the ultimate effect element during CD97 internalization process. Recently, the promoting role of β-arrestin1 in ovarian cancer, lung cancer, prostate cancer, and breast cancer metastasis has been raised. (36) (37) (38) (39) The role of β-arrestin1 in our study can be interpreted in the context of the canonical GPCR trafficking element during CD97 internalization. Our results revealed that overexpression of β-arrestin1 could not affect MMP2/9 expression level but that MMP2/9 increased when β-arrestin1 was knocked down, which indicates that β-arrestin1 functions as a CD97 trafficking element instead of a regulator. Besides, altered CD97 expression significantly affecting MMP2/9 expression adequately documented the regulatory role of CD97 rather than β-arrestin1.
Our data also reveal the significant effect of GRK6 during CD97-mediated tumor progression, when it induces CD97 desensitization. GRK-mediated receptor phosphorylation promotes the binding of β-arrestins, which target many GPCRs for internalization in clathrin-coated vesicles. That is, GRKs phosphorylate activated G protein-coupled receptors, leading to receptor desensitization and down-regulation. The degradation after receptor internalization which led to GPCR down-regulation was confirmed. (32) In view of their canonical role, enhanced levels of a given GRK isoform would suppress G protein-dependent signaling triggered by their preferential GPCR substrates. Conversely, down-regulation of GRKs should promote GPCR cascades. (30) Here, we showed that CD97 homologous desensitization occurs predominantly through phosphorylation of the receptor by GRK6 rather than GRK2. Furthermore, overexpressing GRK6 was accompanied by the reduction of CD97; conversely, knockdown of GRK6 was associated with overexpression of CD97, which indicates the necessary phosphorylating role of GRK6 during CD97 desensitization and degradation. Given that GRK6 phosphorylation of CD97 is the precondition during the CD97 degradation process; that is, by affecting the phosphorylation level of CD97, GRK6 alters the quantity of CD97 internalization, which ultimately leads to receptor degradation. Moreover, GRK6 deficiency is reported to enhance secretion of tumor mediator MMPs, thereby promoting tumor metastasis. (24) Our collective findings suggest that CD97 overexpression, in conjunction with suppression of the regulator GRK6, promotes MMP2 and MMP9 secretion. GRK6 acts as a rate-limiting element in CD97 desensitization and degradation. Meanwhile, CD97 promotes HCC metastasis through the GRK6-MMP2/9-EMT axis. The integrated regulatory interactions between CD97 and GRK6 reduce CD97 internalization and enhance its expression, resulting in MMP secretion and HCC metastasis. In summary, differences in expression of CD97 were detected in human HCC samples, and CD97 plays a stimulatory role in metastasis of human HCC cells in vitro. The mechanism relies on the integrated regulatory interactions between CD97 and GRK6. A decline in GRK6 expression leads to disruption of CD97 phosphorylation. Consequently, phosphorylation-dependent recruitment of β-arrestin1 is reduced, leading to higher activity and expression of CD97 owing to attenuation of receptor desensitization and internalization (Fig. 7) . The synergistic effects of CD97 and GRK6 significantly promote downstream MMP secretion, facilitating HCC metastasis.
